Clene to Provide CNM-Au8® ALS Program Update




Clene to Provide CNM-Au8® ALS Program Update

Webcast set for 8:30 a.m. ET on December 3rd

SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced it plans provide an update on its CNM-Au8 program in ALS, and to host an investor call and webcast at 8:30 am ET on Wednesday, December 3, 2025. The webcast is accessible via the link below or the Investors section of the Company’s website located here.

Webcast Information:
Title: CNM-Au8 ALS Program Update
Presenters: Rob Etherington, CEO and President, Dr. Ben Greenberg, Head of Medical, Michael Hotchkin, Chief Development Officer and a KOL
Date: December 3, 2025
Start Time: 8:30 a.m. ET
Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1744985&tp_key=9fb9583d33
Dial number: 1-877-407-0779 (US) or 1-201-389-0914 (international), Conference ID#13757380

The archived webcast will be available on the Company’s website beginning approximately two hours after the event.

About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc.), is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8^® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8^® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.

About CNM-Au8^®
CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. CNM-Au8^® is a federally registered trademark of Clene Nanomedicine, Inc.

Investor Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
617-283-2856

FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit




FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit

SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit being held on December 11, 2025, in New York, NY.

Thane Wettig, Chief Executive Officer of FibroGen, will participate in a panel titled Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts on Thursday, December 11 at 12:15 PM ET at the Sofitel New York.

FibroGen’s management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at Oppenheimer.

About FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.fibrogen.com. 

For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@fibrogen.com

Zymeworks Announces Participation in Upcoming Conferences




Zymeworks Announces Participation in Upcoming Conferences

• Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera® across HER2-driven gastrointestinal cancers by partner Jazz

• Zymeworks to present a Trial-in-Progress poster for ZW251, a GPC3-targeting antibody-drug conjugate for hepatocellular carcinoma at ASCO GI

• Management will present at J.P. Morgan Healthcare Conference on January 14 at 3:00 pm Pacific Time (PT)

VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced participation in the following upcoming conferences.

ASCO Gastrointestinal Cancers Symposium
January 8-10, 2026
San Francisco, CA

Zymeworks Presentation

Partner Presentations

The majority of abstracts accepted to ASCO GI will be released at 2:00 pm PT/ 5:00 pm Eastern Time (ET) on January 5, 2026. Late-breaking abstracts will be released at 7:00 am PT / 10:00 am ET on their day of presentation at the Symposium and made publicly available online at that time.

J.P. Morgan Annual Healthcare Conference
January 12-16, 2026
San Francisco, CA

Zymeworks’ management will participate in one-on-one meetings and a corporate presentation on January 14, 2026, at 3:00 pm PT.

About Zymeworks Inc.

Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. The Company’s asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera® (zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the early-stage development of innovative medicines. Zymeworks engineered and developed Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Investor inquiries:

Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
ir@zymeworks.com

Media inquiries:

Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)




Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders (the “Company”), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company’s 2021 Inducement Plan, as amended, as a material inducement to employment to two non-executive employees who were not previous employees or directors of the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of any equity awards that are not made under a stockholder approved equity plan.

The equity awards for the two employees were granted in the form of options to purchase an aggregate of 124,000 shares of the Company’s common stock. The option awards have an exercise price equal to the fair market value of an underlying share of Company common stock as of the date of grant and vest over a period of four years, with 25% vesting on the one-year anniversary of the grant date and the remaining 75% vesting in quarterly installments thereafter, subject to acceleration or forfeiture upon the occurrence of certain events as set forth in each new hire’s award agreements.

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, RDH12, and MERTK. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, an approved small-molecule therapy for pharmacologically induced mydriasis, with additional indications in late-stage development for presbyopia and low-light visual disturbances following keratorefractive surgery. The Company is based in Research Triangle Park, NC. For more information, please visit www.opusgtx.com.

Contacts

Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update




Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

Webcast to be held Wednesday, December 3, at 8:00am ET

CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to present results from its Phase 2 clinical trial of silevertinib and provide a program update on Wednesday, December 3, 2025, at 8:00am ET.

Webcast information

The webcast can be accessed under “Events and Presentations” on the Investors section of the Black Diamond website at www.blackdiamondtherapeutics.com. A replay of the webcast will be available following the completion of the event.

About Black Diamond Therapeutics

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 non-small cell lung cancer (NSCLC) trial of silevertinib, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. For more information, please visit www.blackdiamondtherapeutics.com.

From time to time, we may use our website or our LinkedIn profile at www.linkedin.com/company/black-diamond-therapeutics to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.blackdiamondtherapeutics.com. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website or our LinkedIn page is not incorporated into, and does not form a part of, this press release.

Contact

For Investors:
investors@bdtx.com

For Media:
media@bdtx.com

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025




Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025

Information Regarding the Total Number of Voting Rights and 
Total Number of Shares of the Company as of November 30, 2025

(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Market : NYSE Euronext Paris
ISIN Code: FR 0010417345

* Net total = total number of voting rights attached to shares – shares without voting rights

Attachment

• PDF Version

AMPS Achieves HITRUST e1 Certification, Solidifying Commitment to Data Security in Healthcare




AMPS Achieves HITRUST e1 Certification, Solidifying Commitment to Data Security in Healthcare

PHOENIX, Dec. 02, 2025 (GLOBE NEWSWIRE) — AMPS, a healthcare technology solutions company serving self-insured employer groups, payors, healthcare brokers and consultants, and third-party administrators, announced today that its enterprise systems have earned HITRUST e1 Assessment Certification for cybersecurity and information protection.

The HITRUST e1 Certification demonstrates that AMPS has met requirements defined by leading cybersecurity and regulatory frameworks, confirming that foundational controls are in place to protect sensitive healthcare, financial, and organizational data. By achieving this certification, AMPS has validated that its essential cybersecurity hygiene is aligned with authoritative standards such as CISA Cyber Essentials, Health Industry Cybersecurity Practices (HICP) for Small Healthcare Organizations, NIST 171’s Basic Requirements, and NIST IR 7621.

Built on the HITRUST Assurance Program, the e1 Certification reflects independent third-party testing, centralized quality assurance, and alignment with HITRUST’s Cyber Threat Adaptive engine. This ensures AMPS stays current with evolving threat intelligence, enabling stronger readiness against emerging risks such as phishing, ransomware, and brute force attacks. Unlike self-attestation questionnaires, the e1 Assessment is independently validated and scored, providing a higher level of confidence for customers and partners across the healthcare ecosystem.

“As cybersecurity expectations rise, our stakeholders expect credible, validated assurance,” said Jonathan Jeffress, Chief Operating Officer at AMPS. “Achieving the HITRUST e1 Certification demonstrates our commitment to protecting sensitive data, managing operational risk, and maintaining the trust of our members, clients, and partners who depend on our technology to support their most important decisions.”

HITRUST e1 Certification is especially significant for healthcare brokers and consultants who bring AMPS forward during competitive evaluations or RFP processes. The certification confirms that AMPS has established foundational cybersecurity controls that meet industry-recognized expectations and strengthen defensibility throughout the healthcare cost containment lifecycle.

“HITRUST e1 Certification validates the disciplined security processes our teams follow every day,” said Jami Griffiths, Director of Cybersecurity and IT Administration at AMPS. “This achievement reflects our proactive approach to protecting data and our commitment to maintaining a strong security posture as threats evolve. Our clients and partners trust AMPS with critical information, and this certification reinforces that responsibility.”

As AMPS continues to advance its mission across all its solutions, the HITRUST e1 Certification strengthens the organization’s ability to deliver innovative, technology-driven cost savings with trusted cybersecurity at the core. For self-insured organizations, healthcare brokers and consultants, payors, and TPAs, this certification provides clear confidence that AMPS meets the rigorous cybersecurity expectations required in today’s rapidly evolving landscape. For partners seeking reliability, defensibility, and a competitive advantage in their recommendations, AMPS stands out as the clear and trusted choice.

About AMPS
Founded in 2005, Advanced Medical Pricing Solutions (AMPS) is a diversified healthcare technology company supporting transparent, affordable medical and prescription benefits through proprietary software as a service (SaaS) products and tech-enabled services offered across the healthcare payer and employer markets. The company offers a range of products including prospective payment integrity software, high-dollar medical bill review, claim repricing software, reference-based pricing software and services, and transparent pharmacy benefits management, through its business units: ClaimInsight, PriceDynamix, and Drexi. AMPS serves self-insured employers, health plans, TPAs, and individual market aggregators throughout the United States. For more information, visit www.amps.com.

CONTACT: Media Contact
Sarah Roche
Vice President, Global Marketing
AMPS
sroche@amps.com

Cosmos Health CEO Greg Siokas Adds 3,398,055 Shares Year-to-Date 2025 Following Continued November Purchases




Cosmos Health CEO Greg Siokas Adds 3,398,055 Shares Year-to-Date 2025 Following Continued November Purchases

CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that Chief Executive Officer Greg Siokas has further increased his ownership in the Company through continued share acquisitions during November 2025.

Specifically, between 19 November and 28 November 2025, Mr. Siokas executed five transactions, acquiring 301,101 shares.

So far in 2025, he has added 3,398,055 shares to his holdings.

Following these acquisitions, his total ownership has increased to 6,459,985 shares of Cosmos Health.

Greg Siokas, CEO of Cosmos Health, stated: “We recently reported record-breaking Q3 2025 results, and I expect this strong momentum to continue into Q4. Despite our all-time-high achievements in quarterly revenue, gross profit and gross margins, driven by robust growth across all core business segments, our valuation remains under pressure.

I have increased my ownership by well over three million shares since the beginning of the year because I firmly believe Cosmos is well positioned to deliver significant value. I remain committed to supporting the Company in every way necessary so that we can achieve our objectives as we expand globally and advance our pipeline of innovative products.”

Information on Mr. Siokas’s Recent Transactions:
Please refer to the filings on Form 4 filed with the SEC and available on the SEC’s website for more information about the nature of the transactions, including details such as “Ownership Form”, “Transaction Date”, “Amount”, “Price”, and other relevant information regarding the shares acquired by Mr. Siokas.

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.

Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com 

IPSEN – Buy-back programme – Art 5 of MAR – Week 48 – 2025




IPSEN – Buy-back programme – Art 5 of MAR – Week 48 – 2025

Attachment

• EN_IPSEN – Buy-back programme – Art 5 of MAR – Week 48_2025

IPSEN – Buy-back programme – Art 5 of MAR – Week 48 – 2025




IPSEN – Buy-back programme – Art 5 of MAR – Week 48 – 2025

Attachment

• EN_IPSEN – Buy-back programme – Art 5 of MAR – Week 48_2025